MARKET

AMRX

AMRX

Amneal Pharmaceuticals Inc
NASDAQ
7.43
-0.02
-0.27%
After Hours: 7.43 0 0.00% 16:20 07/23 EDT
OPEN
7.45
PREV CLOSE
7.45
HIGH
7.67
LOW
7.36
VOLUME
1.39M
TURNOVER
0
52 WEEK HIGH
7.74
52 WEEK LOW
2.990
MARKET CAP
2.29B
P/E (TTM)
-13.1691
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AMRX last week (0715-0719)?
Weekly Report · 1d ago
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) insiders are still the largest shareholders with 53% stake despite recent sales
51% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is held by the top 5% of the company's shareholders. The company has a large amount of insider ownership, and is growing in value. The top 5 shareholders hold 53% of of the shares in the company. This suggests the company is well owned by institutional investors. It is worth looking at the insider ownership of a company. Amnele Pharmaceuticals has a market cap of US$2.2b.
Simply Wall St · 07/16 13:31
Weekly Report: what happened at AMRX last week (0708-0712)?
Weekly Report · 07/15 09:09
15 Healthcare Stocks Hit New Highs: Did You Spot These Winners?
NASDAQ · 07/14 05:59
U.S. Senate passes bill to trim Big Pharma "patent thickets"
U.S. Senate passes bill to trim Big Pharma "patent thickets" to hinder generic competition. The bill is intended to ease the entrance of biosimilars and other generic drugs onto the market. The Affordable Prescriptions for Patients Act moves next to the U.s. House for consideration.
Seeking Alpha · 07/12 16:35
Press Release: Amneal to Report Second Quarter 2024 Results on August 9, 2024
Dow Jones · 07/11 20:14
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Amneal Pharmaceuticals hit an all-time low in March 2023. The company reported record revenues in Q1 2024. Amneal's share price has increased by >400% since the company's merger with Impax in October 2017. New product launches and international expansion are expected to add billions of dollars of revenues by 2027.
Seeking Alpha · 07/10 15:40
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
FOCINVEZ is a ready-to-use injectable. The single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution. It is indicated in adults and pediatric patients 6 months of age and older for the prevention of nausea and vomiting associated with chemotherapy.
Barchart · 07/09 15:05
More
About AMRX
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Webull offers Amneal Pharmaceuticals Inc stock information, including NASDAQ: AMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMRX stock methods without spending real money on the virtual paper trading platform.